Pharmacodynamic differentiation of lorazepam sleepiness and dizziness using an ordered categorical measure

Journal of Pharmaceutical Sciences

Volumn 99, Issue 8, 2010, Pages 3628-3641

  Kamal, Mohamed A ^a,b   Smith, David E ^b   Cook, Jack ^c   Feltner, Douglas ^c   Moton, Allen ^c   Ouellet, Daniele ^c,d  

^a HOFFMANN LA ROCHE INC   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c PFIZER INC   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

Adverse events; Dizziness; Lorazepam; Ordered categorical; Pharmacodynamics; Sleepiness

Indexed keywords

LORAZEPAM; PLACEBO; HYPNOTIC SEDATIVE AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG LABELING; FEMALE; HUMAN; HUMAN EXPERIMENT; INCIDENCE; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SINGLE DRUG DOSE; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; ALGORITHM; CHEMICALLY INDUCED; COMPUTER SIMULATION; DRUG EFFECTS; PHARMACOKINETICS; POPULATION; SLEEP STAGE; STATISTICAL MODEL; TANDEM MASS SPECTROMETRY;

ADULT; ALGORITHMS; AREA UNDER CURVE; COMPUTER SIMULATION; CROSS-OVER STUDIES; DIZZINESS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; LOGISTIC MODELS; LORAZEPAM; MALE; PHARMACOKINETICS; POPULATION; SLEEP STAGES; TANDEM MASS SPECTROMETRY;

EID: 77955101269     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22093     Document Type: Article

References (32)

1. Jensen M, Karoly P, Braver S. 1986. The measurement of clinical pain intensity: A comparison of six methods. Pain 27:117-126.
2. Lundeberg T, Lund I, Dahlm L, Barg E, Gustafssan C, Sandin L, Rosén A, Kowalski J, Eriksson SV. 2001. Reliability and responsiveness of three different pain assessments. J Rehabil Med 33:279-283.
3. Svensson E. 2000. Comparison of the quality of assessments using continuous and discrete ordinal rating scales. Biometric J 42:417-434.
4. Moton A, Ouellet D, Morlock R, Nyberg J, Feltner D, 2005. Feasibility of assessing differential pharmacodynamic (PD)/adverse events (AE) profiles on CNS agents. Clin Pharmacol Ther 77:P27-P27.
5. Ativan (lorazepam) tablet package insert. Biovail Pharmaceuticals, Inc, Bridewater, NJ 08807, U.S.A.
6. Volkow N, Wang G, Hitzeman R, Fowler J, Pappas N, Lowrimore P, Burr G, Pascani K, Overall J, Wolf A. 1995. Depression of thalamic metabolism by lorazepam is associated with sleepiness. Neuropsychopharmacology 12:123-132.
7. Schreckenberger M, Bartensteina P, Grunderb G. 2004. The thalamus as the generator and modulator of EEG alpha rhythm: A combined PET/EEG study with lorazepam challenge in humans. Neuroimage 22:637-644.
8. Hastie TJ, Botha JL, Schintzler CM. 1989. Regression with an ordered categorical response. Stat Med 8:785-794.
9. Sheiner LB. 1994. A new approach to the analysis of analgesic drug trials, illustrated with bromfenac data. Clin Pharmacol Ther 56:309-322.
10. Mandema JW, Stanski DR. 1996. Population pharmacodynamic models for ketoralac analgesia. Clin Pharmacol Ther 60:619-635.
11. Ette EI, Williams P, Kim Y, Lane J, Liu M, Capparelli EV, 2003. Model appropriateness and population pharmacokinetics modeling. J Clin Pharm 43:610-623. (Pubitemid 36613120)
12. Yano Y, Beal SL, Sheiner LB. 2001. Evaluating pharmacokinetic/ pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 28:171-192. (Pubitemid 33756049)
13. Gibaldi M, Perrier D. 1982. Pharmacokinetics, 2nd edition. Marcel Dekker, Inc New York pp 409-417.
14. Beal SL, Sheiner LB, Boeckmann AJ. 1989 -2006. NONMEM user's guides. Ellicott City, MD: Icon Development Solutions.
15. Mandema JW, Verotta D, Sheiner LB. 1992. Building population pharmacokinetic-Pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm 20:511-528.
16. Ette EI, Ludden TM. 1995. Population pharmacokinetic modeling: The importance of informative graphics. Pharm Res 12:1845-1855.
17. Sheiner LB, Stanski DR, Ham J. 1979. Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to D-tubocurarine. Clin Pharmacol Ther 25:358-371.
18. Frame B, Miller R, Lalonde R. 2003. Evaluation of mixture modeling with count data using NONMEM. J Pharmacokinet Pharmacodyn 30:167-183.
19. Zingmark P, Kagedal M, Karlsson MO. 2005. Modelling a spontaneously reported side effect by use of a markov mixed-effects model. J Pharmacokinet Pharmacodyn 32:261-281.
20. Ito K, Hutmacher M, Liu J, Qiu R, Frame B, Miller R. 2008. Exposure-response analysis for spontaneously reported dizziness in pregabalin-treated patients with generalized anxiety disorder. 84:127-135.
21. Karlsson MO, Savic RM. 2007. Diagnosing model diagnostics. Clin Pharmacol Ther 82:17-20.
22. Greenblatt D. 1981. Clinical pharmacokinetics of oxazepam and lorazepam. Clin Pharmacokinet 6:89-105.
23. Blin O, Jacquet A, Callamand S, Jorive E, Habib M, Gayraud D, Durand A, Brugoerolle B, Pisano P, 1999. Pharmacokinetic-pharmacodynamic analysis of mnesic effects of lorazepam in healthy volunteers. Br J Clin Pharmacol 48:510-512.
24. Ellinwood E, Heatherly D, Nikaido A, Bjornsson T, Kilts C, 1985. Comparative pharmacokinetics and pharmacodynamics of lorazepam, alprazolam and diazepam. Psychopharmacology 86:392-399.
25. Gupta K, Ellinwood H, Heatherly G. 1990. Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of benzodiazepines. I: Lorazepam. J Pharmacokinet Biopharm 18:98-102.
26. Huron C, Giersch A, Danion J. 2002. Lorazepam, sedation, and conscious recollection: A dose-response study with healthy volunteers. Inter Clin Pschopharmacol 17:19-26. (Pubitemid 34056521)
27. Dieterich M. 2004. Dizziness. Neurologist 10:154-164.
28. Hain T, Uddin M. 2003. Pharmacologic treatment of vertigo. CNS Drugs 17:85-100.
29. A/ benzodiazepine receptor heterogeneity: Neurophysiological implications. Neuropharmacology 34:245-254.
30. Mager D, Jusko WJ. 2001. Pharmacodynamic modeling of time-dependent transduction systems. Clin Pharmacol Ther 70:210-216.
31. Girard P. 2005. Clinical Trial Simulation: A tool for understanding study failures and preventing them. Basic Clin Pharmacol Toxicol 96:228-234.
32. Cutler NR. 2001. Pharmacokinetic studies of antipsychotics in healthy volunteers versus patients. J Clin Psychol 62:10-13.